Table 1 Basic Information of Included Studies.

From: Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: a meta-analysis

Study

Country

Study Design

Sample Size IC+CCRT/CCRT

Mean/median Gge (year) IC+CCRT/CCRT

Male/Female IC+CCRT CCRT

Inclusion Period

Complete Treatment IC+CCRT/CCRT

Stage

Radiotherapy

IC

CC

Outcomes

Paccagnella A et al. (2010)18

Italy

multicenter study

50/51

58/60

46/4 38/13

2003.1-2006.1

46/47

UICC stage III-IVM0

primary tumor: 70 Gy (2 Gy/day, 5 days/week for 7weeks) neck: >60 Gy (2 Gy/day, 5 days/week for 5 weeks).

TPF: docetaxel 75 mg/m2 day1, cisplatin 80 mg/m2 day 1, 5-fluorouracil 800 mg/m2/ day1–4. (every 3 weeks for 3 cycles)

Cisplatin 20 mg/m2 day1–4, 5-fluorouracil 800 mg/m2 day1–4 (weeks 1 and 6)

OS, PFS, CR,ORR, Toxicity

Chen et al. (2011)19

China

single-institution study

60/60

55.1/56.5

48/12 46/14

2005.1-2007.6

NR

UICC stage III-IVM0

primary tumor: 66-74 Gy (2 Gy/f × 5 f/week) lymph node(+): 66-70 Gy lymph node(-): 50-54 Gy

Paclitaxel 135-150 mg/m2 day1, cisplatin 75–100 mg/m2 day1 (every 3 weeks for 2 cycles)

Paclitaxel 135-150 mg/m2 day1, cisplatin 75–100 mg/m2day1,day22, day43

OS, PFS, CR, PR, SD, PD, ORR, DMR, LRR, Toxicity

Haddad R et al. (2013)20

USA

multicenter study

70/75

55/54

64/6 63/12

2004.8-2008.12

56/66

AJCC stage III– IVM0

A1: 72 Gy (1.8/1.5 Gy/f × 5 f/week for over 6 weeks) A2: 70 Gy (2.0 Gy/f × 5 f/week for over 7 weeks) B: 72 Gy (1.8/1.5 Gy/f × 5 f/week for over 6 weeks)

TPF: docetaxel 75 mg/m2 day1, cisplatin 100 mg/m2 day1, fluorouracil 1000 mg/m2 day1–4. (every 3 weeks for 3 cycles)

A1: docetaxel 20 mg/m2 (weekly for 4 weeks);A2: weekly carboplatin area under the curve (AUC) 1.5 for 7 weeks as per the TAX 324 study29; B: cisplatin 100 mg/m2 day1,day22

OS, PFS, DMR, LRR, Toxicity

Cohen EE et al. (2014)21

USA

multicenter study

138/135

56.7/56.9

113/25 118/17

2004.12-2009.5

122/130

AJCC stage IVM0

3DCRT/IMRT: 0.15 Gy /f × 2 f/day every other week Total: 74–75 Gy High/Low -risk microscopic: 54 Gy/39 Gy spinal cord: 40 Gy (3DCRT, 45 Gy (IMRT)

TPF: docetaxel 75 mg/m2 day1, cisplatin 75 mg/m2 day1, fluorouracil 750 mg/m2 day1–5 (every 3 weeks for 2 cycles)

Docetaxel 20 mg/m2 and increasing by 5 mg/m2 until 30 mg/m2, fluorouracil 600 mg/m2/ day1–5, hydroxyurea 500 mg PO q12h × 6 days (weeks 1 and 5)

OS, DFFS, RFS, ORR, CR, PR, SD, PD, DMR, LRR, Toxicity

Hitt R et al. (2014)22

Spain

multicenter study

155,156/128

58.1/56.5

145/10 115/13

2002.12-2007.5

137/107

NR

total tumor: 70 Gy (1.8–2.0 Gy/f × 5 f/week ) lymph node: 50 Gy (1.8–2.0 Gy/f × 5 f/week )

TPF: docetaxel 75 mg/m2 day1, cisplatin 75 mg/m2 day1, 5-fluorouracil 750 mg/m2 day1–5. (every 3 weeks for 3 cycles) PF: cisplatin 100 mg/m2 day1, 5-fluorouracil 1000 mg/m2 day1–5. (every 3 weeks for 3 cycles)

Cisplatin 100 mg/m2 (day1, 22 and 43)

OS, PFS, TTF, LRC, Toxicity

  1. Abbreviations: OS: Overall survival, CR: Complete response, RFS: Recurrence-free survival, PFS: Progression-free survival, PR: Partial response, TTF: Time-to-treatment failure, DFFS: Distant failure–free survival, ORR: Overall response rate, LRC: Locoregional control, DMR: Distant metastasis rate, SD: Stable disease, NR: Not report, LRR: Locoregional recurrence rate, PD: Progerssive disease, IMRT: Intensity-modulated radiation therapy, 3DCRT: Three-dimensional conformal radiation therapy.
Back to article page